352 related articles for article (PubMed ID: 11696577)
1. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
[TBL] [Abstract][Full Text] [Related]
2. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
3. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
4. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
6. Role of the histone deacetylase complex in acute promyelocytic leukaemia.
Lin RJ; Nagy L; Inoue S; Shao W; Miller WH; Evans RM
Nature; 1998 Feb; 391(6669):811-4. PubMed ID: 9486654
[TBL] [Abstract][Full Text] [Related]
7. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
8. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy.
Gu BW; Xiong H; Zhou Y; Chen B; Wang L; Dong S; Yu ZY; Lu LF; Zhong M; Yin HF; Zhu GF; Huang W; Ren SX; Gallagher RE; Waxman S; Chen GQ; Wang ZG; Chen Z; Fu G; Chen SJ
Proc Natl Acad Sci U S A; 2002 May; 99(11):7640-5. PubMed ID: 12032336
[TBL] [Abstract][Full Text] [Related]
9. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.
Ruthardt M; Testa U; Nervi C; Ferrucci PF; Grignani F; Puccetti E; Grignani F; Peschle C; Pelicci PG
Mol Cell Biol; 1997 Aug; 17(8):4859-69. PubMed ID: 9234742
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia: from clinic to molecular biology.
Chen SJ; Wang ZY; Chen Z
Stem Cells; 1995 Jan; 13(1):22-31. PubMed ID: 7719245
[TBL] [Abstract][Full Text] [Related]
11. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
12. The RAR alpha-PLZF chimera associated with Acute Promyelocytic Leukemia has retained a sequence-specific DNA-binding domain.
Sitterlin D; Tiollais P; Transy C
Oncogene; 1997 Mar; 14(9):1067-74. PubMed ID: 9070655
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia.
Chen Z; Tong JH; Dong S; Zhu J; Wang ZY; Chen SJ
Genes Chromosomes Cancer; 1996 Mar; 15(3):147-56. PubMed ID: 8721678
[TBL] [Abstract][Full Text] [Related]
14. The molecular biology of acute promyelocytic leukemia.
Slack JL; Gallagher RE
Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
[TBL] [Abstract][Full Text] [Related]
15. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML.
Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E
Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078
[TBL] [Abstract][Full Text] [Related]
16. Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia.
Licht JD; Shaknovich R; English MA; Melnick A; Li JY; Reddy JC; Dong S; Chen SJ; Zelent A; Waxman S
Oncogene; 1996 Jan; 12(2):323-36. PubMed ID: 8570209
[TBL] [Abstract][Full Text] [Related]
17. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
18. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.
Zhang JW; Wang JY; Chen SJ; Chen Z
J Biosci; 2000 Sep; 25(3):275-84. PubMed ID: 11022230
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
